Malaria

Malaria

WHO / Adidja Amani

Malaria remains a major cause of childhood morbidity and mortality, particularly in sub-Saharan Africa, with children under five years of age disproportionately affected. Despite the availability of effective artemisinin-based combination therapies (ACTs), gaps remain in access to age-appropriate formulations, particularly for the youngest children. The emergence and spread of antimalarial drug resistance further highlights the need to optimize existing treatments and accelerate the development of new therapeutic options.

Paediatric Drug Optimization (PADO) for malaria identified priorities to address remaining gaps in age-appropriate antimalarial treatment and prevention, building on important advances in the development of child-friendly formulations. The PADO access list highlighted existing antimalarial formulations requiring targeted efforts to improve availability, affordability and uptake. The priority list emphasized the need to improve treatment options for newborns and young infants, develop child-friendly formulations of specific artemisinin-based combination therapies (ACTs), and address formulation gaps in malaria chemoprophylaxis. The watch list identified promising new combinations, compounds with novel mechanisms of action, and long-acting technologies with potential applications in malaria treatment and prevention. Together, these priorities underscore the importance of expanding treatment and prevention options, while supporting evolving strategies to address antimalarial drug resistance, including the use of multiple first-line therapies.

Portfolio products

15 products · PADO-malaria
● Access list: 4    ● Priority list: 3    ● Watch list: 8
4 Access
3 Priority
8 Watch

PADO-malaria access list 4
Artemether oily injection
20 mg/mL
Primaquine
2.5 mg dispersible tablet
Tafenoquine
50 mg dispersible tablet
Artesunate–pyronaridine
Granules: 20 mg + 60 mg
PADO-malaria priority list 3
Artemether–lumefantrine
2.5/30 mg dispersible tablet
Artesunate–amodiaquine
25/67.5 mg and 50/135 mg child-appropriate oral dosage forms such as coated micropellets, dispersible tablets
Atovaquone–proguanil
62.5/25 mg dispersible tablets
PADO-malaria watch list 8
Artesunate–piperaquine
Artemether + lumefantrine + amodiaquine
Sulfadoxine–pyrimethamine + artesunate–pyronaridine
Ganaplacide–lumefantrine
Cipargamin
ZY 19489 + ferroquine
M5717 + pyronaridine
Long-acting technologies

Portfolio Update
  • Artemether-lumefantrine 2.5/30 mg dispersible tablets: Now prequalified and recommended by WHO (see WHO Guidelines for Malaria reference below).

PADO report

Paediatric drug optimization for malaria: meeting report, 24-26 June 2025
This report provides a synthesis of the outcomes of the first paediatric drug optimization exercise that was held for Malaria. The PADO for malaria meeting...

Contact

Peter Olumese
Email: olumesep@who.int

Related publications

WHO guidelines for malaria

The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate...

News